Discovery of Oral and Inhaled PDE4 Inhibitors

Pauline C. Ting,Joe F. Lee,Rongze Kuang,Jianhua Cao,Danlin Gu,Ying Huang,Zhidan Liu,Robert G. Aslanian,Kung-I. Feng,Daniel Prelusky,James Lamca,Aileen House,Jonathan E. Phillips,Peng Wang,Ping Wu,Daniel Lundell,Richard W. Chapman,Chander S. Celly
DOI: https://doi.org/10.1016/j.bmcl.2013.08.056
IF: 2.94
2013-01-01
Bioorganic & Medicinal Chemistry Letters
Abstract:The optimization of oxazole-based PDE4 inhibitor 1 has led to the identification of both oral (compound 16) and inhaled (compound 34) PDE4 inhibitors. Selectivity against PDE10/PDE11, off target screening, and in vivo activity in the rat are discussed.
What problem does this paper attempt to address?